Sermorelin vs Tesamorelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Geref, GRF 1-29
A truncated analog of natural GHRH containing the first 29 amino acids. Previously FDA-approved for pediatric GH deficiency, now used off-label for adult hormone optimization.
Also: Egrifta, Egrifta WR
An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. New F8 formulation (Egrifta WR) approved March 2025 allows weekly reconstitution vs daily.
Key Comparison Insights
- Tesamorelin is FDA approved, while Sermorelin remains in research stages.
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- Tesamorelin has stronger research evidence (FDA Approved) compared to Sermorelin (Animal Studies).
Detailed Comparison
| Attribute | Sermorelin | Tesamorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Sermorelin is bioidentical to the active portion of endogenous GHRH. It stimulates the pituitary's natural production and release of growth hormone, maintaining normal feedback mechanisms and pulsatile GH release patterns. | Tesamorelin is a stabilized analog of human GHRH that stimulates the pituitary to release growth hormone. It specifically reduces visceral adipose tissue (VAT) while having minimal effect on subcutaneous fat, likely through GH-mediated lipolysis. |
| Common Dosing | 200-500 mcg before bed Once daily, typically before bed | 2 mg daily (F8: 1.28 mg daily) Once daily |
| Administration | Subcutaneous injection at bedtime | Subcutaneous injection |
| Typical Duration | 3-6 months typical | Indefinite for approved indication |
| Best Time to Take | Before bed (fasted) | Before bed (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Extensive clinical research from FDA approval process. Studies demonstrate restoration of youthful GH levels, improved sleep quality, increased lean body mass, and enhanced recovery. Generally preserves natural GH axis better than exogenous GH. | FDA approved based on trials showing 15-20% reduction in visceral adipose tissue over 26 weeks. March 2025: FDA approved new F8 formulation (Egrifta WR) with weekly reconstitution, reducing patient burden. CROI 2025 data highlighted limitations of BMI for cardiovascular risk assessment in HIV patients. |
Frequently Asked Questions: Sermorelin vs Tesamorelin
What is the difference between Sermorelin and Tesamorelin?
Sermorelin is a growth hormone peptide that a truncated analog of natural ghrh containing the first 29 amino acids. previously fda-approved for pediatric gh deficiency, now used off-label for adult hormone optimization. Tesamorelin is a growth hormone peptide that an fda-approved ghrh analog used to reduce excess abdominal fat in hiv-infected patients with lipodystrophy. new f8 formulation (egrifta wr) approved march 2025 allows weekly reconstitution vs daily. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Sermorelin or Tesamorelin?
Neither is universally "better" - the choice depends on your specific goals. Sermorelin is typically used for growth hormone purposes, while Tesamorelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Sermorelin and Tesamorelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Sermorelin and Tesamorelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.